Optellum

Optellum’s vision is to radically reshape cancer care from early diagnosis to treatment.

Optellum’s vision is to radically reshape cancer care, by enabling every clinician to choose the optimal diagnostic and treatment pathway for their patient. We do that by providing expert-level decision support for personalised diagnosis and treatment, based on collective experience of thousands of doctors, pooled by applying Machine Learning to vast medical image and patient record repositories.

Our first suite of products targets patient risk stratification for lung cancer – the world’s deadliest and commonest cancer – from early diagnosis through to treatment. We are a team of award-winning AI and imaging experts who met at Oxford’s world-renowned computer vision laboratory, and we have track records of bringing innovation to market (including multiple trade sales, IPO). We are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning and diagnostic imaging; and Oxford's most prominent investors with track records in medtech startups.

08/03/2024

This International Women's Day we're launching our Q&A with our investor Dr Tara Bishop of Black Opal Ventures, taking about the collision of healthcare and technology and what inspires her to invest in companies like Optellum.

Introducing Dr Tara Bishop, Black Opal Ventures, and the Optellum Virtual Nodule Clinic. Part of our celebration of International Women's Day 2024.

Address

Oxford Centre For Innovation
Oxford
OX11BY

Website

http://www.optellum.com/

Alerts

Be the first to know and let us send you an email when Optellum posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Early Interception of Lung Cancer

Optellum’s vision is to redefine cancer care, by enabling every clinician, in every hospital, to manage their patients in the optimal way.

We do that by providing end-end IT platform for personalized early diagnosis and therapy, based on the collective experience of thousands of doctors pooled by machine learning applied to vast patient datasets.

Our first suite of products targets management of patients at high risk of developing lung cancer – the world’s deadliest and commonest cancer – from early diagnosis through to treatment.

Optellum comprises a team of award-winning medical imaging software, AI, and clinical experts who met at Oxford’s world-renowned computer vision lab. Between us, we have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. We are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning ; and Oxford's most prominent investors.